France
Xegen is a specialized bioinformatics company established in 2012 with a focus on Next Generation Sequencing (NGS) data analysis. Based in France, Xegen addresses complex NGS data processing challenges by providing specific, automated, and high-value bioinformatics analyses to its customers and partners.
The company is particularly notable for developing Polypheme, a comprehensive bioinformatics suite specialized in the analysis of complex genes and polymorphisms detection. Polypheme supports both classic (like HLA-A, -B, -C, DRB1, DQB1) and non-classic genes (such as HLA-E, -F, -G, -H), and aids in the discovery of new alleles, representative of Xegen's cutting-edge capabilities in leveraging bioinformatics for genomic exploration.
The company's initial investment was a spinout on 01 July 2012, backed by notable entities like SATT Sud-Est, CNRS Innovation, and the French National Centre for Scientific Research - CNRS. Positioned at the intersection of Biotechnology and Clean Energy, Xegen presents significant growth potential for investors interested in advanced genomic solutions and sustainable innovation.
